10-K/A: Bioxytran Inc. Files Amended 10-K, Cites Material Weakness in Internal Controls

Bioxytran Inc. has filed an amended annual report on Form 10-K, restating its financials for 2023 and 2022 due to errors in share valuation and reporting, while also disclosing a material weakness in internal controls.

Summary

• Bioxytran Inc., a clinical-stage pharmaceutical company, has filed an amended annual report on Form 10-K, restating its financial statements for the years ended December 31, 2023, and 2022.
• The restatement was due to errors in the valuation of shares issued under certain exemptions and timing issues with accruals.
• The company reported a net loss of $4,472,525 for 2023, compared to a net loss of $2,473,134 in 2022.
• Research and development expenses were $1,149,209 in 2023 and $1,277,768 in 2022.
• General and administrative expenses increased to $2,651,003 in 2023 from $1,158,773 in 2022, primarily due to increased payroll and stock promotional activities.
• The company's cash balance decreased from $295,401 at the end of 2022 to $26,086 at the end of 2023.
• The company has a negative working capital of $3,218,152 as of December 31, 2023, and an accumulated deficit of $15,699,327.
• The company has convertible notes outstanding with a total face value of $1,900,000.
• The company needs to raise at least $3,700,000 to continue operations for the next 15 months.
• The company has identified a material weakness in its internal control over financial reporting due to a lack of segregation of duties.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, a material weakness in internal controls, and a dependence on future capital raises, which are all negative indicators. While there is some progress in drug development, the overall outlook is concerning from an investment perspective.

Positives

• The company has made progress in its drug development programs, with BXT-25 successfully tested in animals and IND approvals for ProLectin-M.
• Bioxytran has a scientific and medical advisory board consisting of leading physicians and experts.
• The company has a strategic objective to license its drugs to large pharmaceutical companies.

Negatives

• The company has a history of losses and has not generated any revenue since inception.
• The company has a significant accumulated deficit of $15,699,327.
• The company's cash reserves are critically low, with only $26,086 on hand at the end of 2023.
• The company has a negative working capital of $3,218,152.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is dependent on raising additional capital to continue operations.

Risks

• The company may not be able to achieve or maintain profitability.
• The company has a limited operating history, making it difficult to evaluate its future prospects.
• The company will require additional financing, which may not be available on favorable terms or at all.
• Raising additional capital may cause dilution to stockholders.
• The company's products are based on novel, unproven technologies.
• Clinical drug development is a lengthy and expensive process with an uncertain outcome.
• The company may be unable to commercialize its drug candidates.
• The company's success depends on its ability to retain key executives and attract qualified personnel.
• The company will need regulatory approvals to commercialize its products.
• The company's competitive position depends on the protection of its intellectual property.
• The market for the company's proposed products is rapidly changing and competitive.
• The company may become involved in lawsuits to protect or enforce patents.
• The company must implement additional and expensive finance and accounting systems as it grows.

Future Outlook

The company plans to seek additional capital through private placements and public offerings of its Common Stock. The company intends to develop its drugs to the point where they can be licensed to large pharmaceutical companies.

Management Comments

• Management plans to seek additional capital through private placements and public offerings of its Common Stock.
• Management believes that if they can raise $3,700,000, they will have sufficient working capital to develop their business over the next 15 months.

Industry Context

The company operates in the competitive pharmaceutical industry, focusing on novel therapies for hypoxia and viral diseases. The company's approach to using co-polymers and galectin antagonists is unique, but faces competition from existing therapies and other companies developing new treatments.

Comparison to Industry Standards

• Bioxytran's financial situation, with its significant losses and low cash reserves, is not uncommon for early-stage biotech companies.
• However, the material weakness in internal controls is a concern and needs to be addressed to meet industry standards for public companies.
• The company's reliance on external funding is typical for biotech startups, but the level of funding required and the uncertainty of securing it are significant risks.
• Compared to companies like La Jolla Pharmaceuticals (LJPC) and Galectin Therapeutics (GALT), which were founded by the same individual, Bioxytran is at an earlier stage of development and faces greater financial challenges.
• The company's focus on novel technologies, such as co-polymer-based oxygen carriers and galectin antagonists, is similar to other biotech companies pursuing innovative therapies, but the success of these technologies is not guaranteed.

Related Party Transactions

• The company has license agreements with two affiliated companies where the officers of the company hold a majority interest.
• The company issued shares to an affiliate to offset invoices paid on behalf of the company and accrued salaries to officers.
• The company received an interest-free loan from an affiliated company.

Stakeholder Impact

• Shareholders face significant dilution risk due to potential capital raises and convertible note conversions.
• Employees face uncertainty due to the company's financial instability.
• Customers and patients may be impacted by delays in drug development and commercialization.
• Creditors face the risk of non-payment due to the company's low cash reserves.

Next Steps

• The company intends to proceed with a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats as funding permits.
• The company plans to start clinical trials for ProLectin-M in the first quarter of 2024, provided they obtain adequate funding.
• The company intends to issue a Private Placement Offering under Regulation D in the order of $4 million in the spring of 2025.

Key Dates

Keywords

Bioxytran, pharmaceutical, hypoxia, BXT-25, ProLectin, stroke, COVID-19, clinical trials, internal controls, financial reporting, convertible notes, stock options, drug development, FDA approval, capital raise